drugset / Trial / NCT06828354

A Study of SHR-A1811 in Subjects With Ovarian Cancer

NCT06828354

Phase 3 Recruiting 300 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

Timeline

Start
2025-03-13
Primary completion
2027-05
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxorubicin Other / unclassified
Comparator Gemcitabine Small molecule
Comparator Paclitaxel Small molecule
Comparator Topotecan Small molecule
Subject Trastuzumab Rezetecan Monoclonal antibody

Indications